By Phillip McLeod
The Brazilian Health Regulatory Agency (ANVISA) has approved ropeginterferon alfa-2b (BESREMi) for the treatment of adult patients with polycythemia vera (PV). This approval was announced on March 20, 2025.
Ropeginterferon alfa-2b offers prolonged activity and is administered every two weeks, or every four weeks if hematological stability is maintained, according to the therapy’s manufacturers, Pint Pharma and PharmaEssentia.
In Brazil, DataSUS, the IT department of the Brazilian Unified Health System, recorded 1,843 cases of PV between 2016 and 2020, with an incidence of 0.16 per 100,000 inhabitants, according to the press release announcing the therapy’s approval.
